“FLipping” the story: FLT3-mutated acute myeloid leukemia and the evolving role of FLT3 inhibitors

TE Knight, H Edwards, S Meshinchi, JW Taub, Y Ge - Cancers, 2022 - mdpi.com
Simple Summary Patients with acute myeloid leukemia (AML) may have a number of
different mutations. Those with mutations in the FLT3 gene have a higher risk of relapse and …

Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes

S Shimony, RM Stone, M Stahl - Current Opinion in Hematology, 2022 - journals.lww.com
Venetoclax combination therapy in acute myeloid leukemia and... : Current Opinion in
Hematology Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic …

[PDF][PDF] 急性髓系白血病造血干细胞移植后复发的预防及治疗

仲照东, 陈智超, 夏凌辉 - 临床血液学杂志, 2022 - whuhzzs.com
异基因造血干细胞移植是目前治愈急性髓系白血病(acutemyeloidleukemia, AML) 的唯一方法,
但超过30% 的AML 患者存在移植后复发. 复发患者预后不佳, 2 年的总生存(OS) 率不足15 …

Transplant for TP53-mutated MDS and AML: because we can or because we should?

J Versluis, RC Lindsley - Hematology, 2022 - ashpublications.org
TP53 mutations impair the cellular response to genotoxic stress and drive intrinsic
resistance to conventional cytotoxic therapies. Clinical outcomes in patients with TP53 …

Current status and perspectives of allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia

S Servais, Y Beguin, F Baron - Stem Cells Translational …, 2022 - academic.oup.com
As in younger patients, allogeneic stem cell transplantation (alloHSCT) offers the best
chance for durable remission in older patients (≥ 60 years) with acute myeloid leukemia …

Prevention and treatment of relapse after hematopoietic stem cell transplantation in acute myeloid leukemia

Z Zhaodong, C Zhichao, XIA Linghui - J Clin Hematol, 2022 - lcxyen.whuhzzs.com
Prevention and treatment of relapse after hematopoietic stem cell transplantation in acute
myeloid leukemia Homepage Journals 1.{{journal.titleEn}} {{journal.titleEn}} {{journal.titleEn}} …